Rivastigmine
Also known as: Exelon · Prometax · Rivastigmine Sandoz · Rivastigmine 1 A Pharma · Rivastigmine Hexal · Nimvastid · Rivastigmine Actavis · Rivastigmine Transdermal System
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, rivastigmine is indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia and mild to moderately severe dementia in patients with idiopathic Parkinson's disease. In the United States, the rivastigmine transdermal system is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type, as well as mild-to-moderate dementia associated with Parkinson's disease. The cited source lists rivastigmine as having an approved use for Alzheimer disease.
From: Source: European Medicines Agency (EMA), Exelon — EPAR, 24/02/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 183379 rivastigmine
- EMA
- EMEA/H/C/000169, EMEA/H/C/000255, EMEA/H/C/001183, EMEA/H/C/001181, EMEA/H/C/001182, EMEA/H/C/001029, EMEA/H/C/002036
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Exelon
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Source: European Medicines Agency (EMA), Exelon — EPAR, 24/02/2026. © European Medicines Agency.
Document date: 24/02/2026 · Official document →
EMA (EU) Prometax
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Source: European Medicines Agency (EMA), Prometax — EPAR, 15/04/2025. © European Medicines Agency.
Document date: 15/04/2025 · Official document →
FDA (USA) Rivastigmine
1 INDICATIONS AND USAGE Rivastigmine transdermal system is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer's type (AD) ( 1.1 ) Mild-to-moderate dementia associated with Parkinson's disease (PD) ( 1.2 ) 1.1 Alzheimer’s Disease Rivastigmine transdermal system is indicated for the treatment of dementia of the Alzheimer's type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease. 1.2 Parkinson’s Disease Dementia Rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with Parkinson's disease (PDD).
Data provided by the U.S. Food and Drug Administration.
Document date: 20251114 · Official document →
EMA (EU) Rivastigmine 1 A Pharma
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Source: European Medicines Agency (EMA), Rivastigmine 1 A Pharma — EPAR, 20/08/2026. © European Medicines Agency.
Document date: 20/08/2026 · Official document →
EMA (EU) Rivastigmine Hexal
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Source: European Medicines Agency (EMA), Rivastigmine Hexal — EPAR, 20/08/2026. © European Medicines Agency.
Document date: 20/08/2026 · Official document →
EMA (EU) Rivastigmine Sandoz
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Source: European Medicines Agency (EMA), Rivastigmine Sandoz — EPAR, 20/08/2026. © European Medicines Agency.
Document date: 20/08/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Alzheimer disease Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Rivastigmine approved for in the European Union?
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. (Source: European Medicines Agency (EMA), Exelon — EPAR, 24/02/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Exelon — EPAR, 24/02/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Prometax — EPAR, 15/04/2025. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Rivastigmine 1 A Pharma — EPAR, 20/08/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Rivastigmine Hexal — EPAR, 20/08/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Rivastigmine Sandoz — EPAR, 20/08/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.